Voxelotor for Sickle Cell Disease (ActIVe Trial)

"Due to its Phase 4 status, Voxelotor is considered safe and received a score of 3 on our safety scale."

"Per the information hosted on clinicaltrials.gov, this research is not recruiting candidates at present. This study was initially posted to the platform in October of 2020 and last updated in April 2022; however, 205 other trials are actively enlisting participants currently."

"Currently, 7 trials are being conducted on Voxelotor - 3 of which are in the advanced Phase 3 stage. Although mostly concentrated around Atlanta, Georgia, 139 sites across America have been selected to host studies for this drug's efficacy and safety."

"At present, the trial is running in 10 sites across the US. Participants can pick from locations such as New york, Houston and Bronx along with other nearby areas. It is recommended to choose a site close to you so that travelling costs are minimized if you decide to participate."

"Patients aged between 12 and 55 years old may be eligible to join this trial, while those younger than 12 or older than 65 have 137 and 89 trials respectively that they can partake in."

"Presently, Global Blood Therapeutics' drug Voxelotor is being trialled at 39 distinct locations across 14 countries. The first trial for this medication began in 2016 and enrolled 155 participants before progressing to Phase 2 approval. Since then, 11 additional trials have been successfully completed."

"Patients aged 12 to 55 who have been diagnosed with sickle cell anemia are eligible for inclusion in this clinical trial, of which 25 participants will be accepted."

"This clinical trial is no longer taking on any new patients. It was initially posted in October 2020 and last updated April 2022. Individuals looking for other trials may be interested to know that there are 198 studies currently recruiting participants with sickle cell anemia, as well as 7 separate trials involving Voxelotor medication."